Total Payments
$374,933
2024 Payments
$660.17
Companies
20
Transactions
794
Medicare Patients
3,213
Medicare Billing
$279,104
Payment Breakdown by Category
Other$232,789 (62.1%)
Research$55,892 (14.9%)
Travel$55,781 (14.9%)
Consulting$16,088 (4.3%)
Food & Beverage$14,050 (3.7%)
Education$333.16 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $216,789 | 95 | 57.8% |
| Unspecified | $55,892 | 9 | 14.9% |
| Travel and Lodging | $55,781 | 330 | 14.9% |
| Consulting Fee | $16,088 | 5 | 4.3% |
| Honoraria | $16,000 | 3 | 4.3% |
| Food and Beverage | $14,050 | 346 | 3.7% |
| Education | $333.16 | 6 | 0.1% |
Payments by Type
General
$319,041
785 transactions
Research
$55,892
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $237,758 | 576 | $0 (2022) |
| Aerie Pharmaceuticals, Inc. | $101,555 | 122 | $0 (2021) |
| Iridex Corporation | $16,022 | 5 | $0 (2024) |
| ABBVIE INC. | $9,919 | 28 | $0 (2024) |
| Alcon Vision LLC | $6,355 | 16 | $0 (2024) |
| Perrigo Company plc | $1,383 | 2 | $0 (2019) |
| Bausch & Lomb Americas Inc. | $312.16 | 15 | $0 (2023) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $288.88 | 7 | $0 (2021) |
| Tarsus Pharmaceuticals, Inc. | $181.30 | 2 | $0 (2024) |
| Amgen Inc. | $177.05 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $660.17 | 11 | Tarsus Pharmaceuticals, Inc. ($181.30) |
| 2023 | $5,862 | 25 | ABBVIE INC. ($5,487) |
| 2022 | $28,878 | 50 | Iridex Corporation ($16,000) |
| 2021 | $46,588 | 76 | Aerie Pharmaceuticals, Inc. ($23,520) |
| 2020 | $61,399 | 83 | Aerie Pharmaceuticals, Inc. ($31,576) |
| 2019 | $105,296 | 259 | Allergan Inc. ($74,115) |
| 2018 | $92,215 | 234 | Allergan Inc. ($75,257) |
| 2017 | $34,034 | 56 | Allergan Inc. ($33,625) |
All Payment Transactions
794 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: EYE CARE | ||||||
| 12/03/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $141.81 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 09/10/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: EYE CARE | ||||||
| 07/16/2024 | Dompe US, Inc. | OXERVATE (Drug) | Food and Beverage | In-kind items and services | $101.11 | General |
| Category: SOLUTION/ DROPS | ||||||
| 06/27/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/23/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $137.15 | General |
| Category: Ophthalmology | ||||||
| 05/21/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $121.16 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/05/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/20/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $11.96 | General |
| Category: Ophthalmology | ||||||
| 01/30/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $39.49 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 01/23/2024 | Iridex Corporation | — | Food and Beverage | Cash or cash equivalent | $6.21 | General |
| 12/13/2023 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $6.47 | General |
| Category: EYE CARE | ||||||
| 11/10/2023 | ABBVIE INC. | LUMIGAN (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,675.00 | General |
| Category: EYE CARE | ||||||
| 11/03/2023 | ABBVIE INC. | LUMIGAN (Drug) | Travel and Lodging | In-kind items and services | $27.91 | General |
| Category: EYE CARE | ||||||
| 11/03/2023 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $3.11 | General |
| Category: EYE CARE | ||||||
| 11/02/2023 | ABBVIE INC. | LUMIGAN (Drug) | Travel and Lodging | In-kind items and services | $931.25 | General |
| Category: EYE CARE | ||||||
| 11/02/2023 | ABBVIE INC. | LUMIGAN (Drug) | Travel and Lodging | In-kind items and services | $556.30 | General |
| Category: EYE CARE | ||||||
| 11/02/2023 | ABBVIE INC. | LUMIGAN (Drug) | Travel and Lodging | In-kind items and services | $162.94 | General |
| Category: EYE CARE | ||||||
| 11/02/2023 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $36.26 | General |
| Category: EYE CARE | ||||||
| 11/02/2023 | ABBVIE INC. | LUMIGAN (Drug) | Travel and Lodging | In-kind items and services | $9.17 | General |
| Category: EYE CARE | ||||||
| 11/02/2023 | ABBVIE INC. | LUMIGAN (Drug) | Travel and Lodging | In-kind items and services | $5.00 | General |
| Category: EYE CARE | ||||||
| 09/26/2023 | Bausch & Lomb Americas Inc. | MIEBO (Drug) | Food and Beverage | In-kind items and services | $121.37 | General |
| Category: Ophthalmology | ||||||
| 09/19/2023 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: EYE CARE | ||||||
| 08/10/2023 | ABBVIE INC. | ALPHAGAN P (Drug), LUMIGAN | Food and Beverage | In-kind items and services | $6.87 | General |
| Category: EYE CARE | ||||||
| 08/08/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $29.14 | General |
| Category: TEPEZZA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Efficacy and Safety of Bimatoprost Sustained-Release SR in Patients With Open-angle Glaucoma or Ocular Hypertension | Allergan Inc. | $27,275 | 2 |
| Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia | Allergan Inc. | $23,862 | 4 |
| Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia | Allergan, Inc. | $4,755 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 562 | 1,053 | $250,264 | $50,155 |
| 2022 | 9 | 680 | 1,230 | $290,361 | $59,109 |
| 2021 | 12 | 894 | 1,527 | $416,045 | $81,506 |
| 2020 | 13 | 1,077 | 1,555 | $402,716 | $88,335 |
Total Patients
3,213
Total Services
5,365
Medicare Billing
$279,104
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 195 | 512 | $74,240 | $28,908 | 38.9% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 125 | 192 | $57,792 | $7,602 | 13.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 77 | $15,708 | $6,406 | 40.8% |
| 92133 | Imaging of optic nerve | Office | 2023 | 164 | 244 | $96,136 | $5,752 | 6.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $4,816 | $1,301 | 27.0% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 12 | 12 | $1,572 | $186.59 | 11.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 226 | 589 | $85,405 | $33,640 | 39.4% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 132 | 197 | $59,297 | $7,861 | 13.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 86 | $17,544 | $7,076 | 40.3% |
| 92133 | Imaging of optic nerve | Office | 2022 | 177 | 267 | $105,198 | $6,441 | 6.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $5,418 | $2,106 | 38.9% |
| 92100 | Multiple measurements of eye fluid pressure over an extended time period | Office | 2022 | 12 | 12 | $2,028 | $725.78 | 35.8% |
| 92134 | Imaging of retina | Office | 2022 | 21 | 22 | $8,668 | $653.96 | 7.5% |
| 92020 | Exam of the internal drainage system of eye | Office | 2022 | 25 | 25 | $3,275 | $495.27 | 15.1% |
| 76514 | Ultrasound scan of cornea to determine thickness | Office | 2022 | 14 | 14 | $3,528 | $109.92 | 3.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 256 | 722 | $104,690 | $45,893 | 43.8% |
| 92083 | Measurement of field of vision during daylight conditions, extended examination | Office | 2021 | 162 | 228 | $68,628 | $9,106 | 13.3% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2021 | 185 | 254 | $100,076 | $6,408 | 6.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 49 | 62 | $12,648 | $4,815 | 38.1% |
| 65855 | Laser repair to improve eye fluid flow, 1 or more sessions | Office | 2021 | 13 | 22 | $75,900 | $4,136 | 5.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 34 | 34 | $10,234 | $3,953 | 38.6% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 75 | 78 | $16,302 | $3,775 | 23.2% |
| 92100 | Multiple measurements of eye fluid pressure over an extended time period, same day | Office | 2021 | 21 | 21 | $3,549 | $1,328 | 37.4% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 27 | 32 | $12,608 | $917.18 | 7.3% |
| 92020 | Examination of cornea and iris using lens device and slit lamp | Office | 2021 | 30 | 32 | $4,192 | $576.14 | 13.7% |
About Dr. Thomas Mundorf, MD
Dr. Thomas Mundorf, MD is a Ophthalmology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821026980.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Mundorf, MD has received a total of $374,933 in payments from pharmaceutical and medical device companies, with $660.17 received in 2024. These payments were reported across 794 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($216,789).
As a Medicare-enrolled provider, Mundorf has provided services to 3,213 Medicare beneficiaries, totaling 5,365 services with total Medicare billing of $279,104. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Charlotte, NC
- Active Since 06/29/2006
- Last Updated 09/21/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1821026980
Products in Payments
- LUMIGAN (Drug) $154,715
- Rhopressa (Drug) $41,359
- RESTASIS (Drug) $38,765
- rocklatan (Drug) $26,217
- rhopressa (Drug) $17,484
- RESTASIS MULTIDOSE (Drug) $8,917
- ALPHAGAN P (Drug) $5,844
- Rocklatan (Drug) $5,149
- COMBIGAN (Drug) $3,827
- VYZULTA (Drug) $477.41
- VUITY (Drug) $368.73
- DURYSTA (Drug) $340.82
- XDEMVY (Drug) $181.30
- TEPEZZA (Biological) $177.05
- XIIDRA (Drug) $156.19
- NGENUITY (Device) $126.13
- MIEBO (Drug) $121.37
- OXERVATE (Drug) $101.11
- PROKERA (Device) $99.29
- TEPEZZA (Drug) $95.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Charlotte
Jeffery Machat
Ophthalmology — Payments: $47,862
Ophthalmology $47,862
Charles Blotnick, M.d, M.D
Ophthalmology — Payments: $17,742
Ophthalmology $17,742
Dr. Herbert Greenman, M.d, M.D
Ophthalmology — Payments: $13,534
Ophthalmology $13,534
Royce Syracuse, Md, MD
Ophthalmology — Payments: $12,267
Ophthalmology $12,267
Dr. Adrian Elfersy, M.d, M.D
Ophthalmology — Payments: $12,255
Ophthalmology $12,255
Ronald Milam, M.d, M.D
Ophthalmology — Payments: $8,420
Ophthalmology $8,420